TY - JOUR
T1 - MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas
AU - Lubezky, Nir
AU - Loewenstein, Shelly
AU - Ben-Haim, Menahem
AU - Brazowski, Eli
AU - Marmor, Sylvia
AU - Pasmanik-Chor, Metsada
AU - Oron-Karni, Varda
AU - Rechavi, Gideon
AU - Klausner, Joseph M.
AU - Lahat, Guy
N1 - Funding Information:
This work was supported by the generous donation of the Enav Family Foundation for Pancreatic Cancer Research .
PY - 2013/5
Y1 - 2013/5
N2 - Background: Intraductal papillary mucinous neoplasms (IPMN) represent a spectrum of tumors that range from low-grade (LG) dysplastic tumors to invasive cancer. Identification of IPMN at high risk for malignant transformation is important for the prevention and early treatment of pancreatic cancer. The roles of microRNA expression in the development of IPMN have not been extensively evaluated. Methods: Expression patterns of 846 human microRNAs (miRNAs) was analyzed using microRNA microarray in 55 tissues, including LG IPMN (n = 10), moderate-grade (MG) IPMN (n = 5), high-grade (HG) IPMN (n = 5), invasive cancer with IPMN (IPMC; n = 10), pancreatic ductal adenocarcinoma without IPMN (PDA; n = 5), LG IPMN extracted from specimens that contain IPMC (LG-Ca; n = 10), and normal pancreatic tissues (n = 10). Results: Fourteen miRNAs were differentially expressed in all IPMN tissues compared with normal pancreatic tissue. Expression level of 3 miRNAs was proportional to dysplasia level. Hierarchical clustering demonstrated grouping of 2 IPMN subgroups: LG and MG IPMN verses HG IPMN and IPMC. Expression of 15 miRNAs was significantly different between these groups. LG-Ca tissues clustered with the HG IPMC group, and 12 miRNAs were differentially expressed in LG-Ca, HG lesions, and IPMC compared with LG lesions. The expression patterns of selected miRNAs were validated using quantitative reverse-transcription real-time polymerase chain reaction. Hierarchical clustering demonstrated microRNA expression profile in IPMC was significantly different from PDA, suggesting that different pathways are involved in these cancer types. Conclusion: This study demonstrates that miRNAs are involved in the development and progression of IPMN. We identified potential targets for diagnosis, prognostication, and treatment of IPMN.
AB - Background: Intraductal papillary mucinous neoplasms (IPMN) represent a spectrum of tumors that range from low-grade (LG) dysplastic tumors to invasive cancer. Identification of IPMN at high risk for malignant transformation is important for the prevention and early treatment of pancreatic cancer. The roles of microRNA expression in the development of IPMN have not been extensively evaluated. Methods: Expression patterns of 846 human microRNAs (miRNAs) was analyzed using microRNA microarray in 55 tissues, including LG IPMN (n = 10), moderate-grade (MG) IPMN (n = 5), high-grade (HG) IPMN (n = 5), invasive cancer with IPMN (IPMC; n = 10), pancreatic ductal adenocarcinoma without IPMN (PDA; n = 5), LG IPMN extracted from specimens that contain IPMC (LG-Ca; n = 10), and normal pancreatic tissues (n = 10). Results: Fourteen miRNAs were differentially expressed in all IPMN tissues compared with normal pancreatic tissue. Expression level of 3 miRNAs was proportional to dysplasia level. Hierarchical clustering demonstrated grouping of 2 IPMN subgroups: LG and MG IPMN verses HG IPMN and IPMC. Expression of 15 miRNAs was significantly different between these groups. LG-Ca tissues clustered with the HG IPMC group, and 12 miRNAs were differentially expressed in LG-Ca, HG lesions, and IPMC compared with LG lesions. The expression patterns of selected miRNAs were validated using quantitative reverse-transcription real-time polymerase chain reaction. Hierarchical clustering demonstrated microRNA expression profile in IPMC was significantly different from PDA, suggesting that different pathways are involved in these cancer types. Conclusion: This study demonstrates that miRNAs are involved in the development and progression of IPMN. We identified potential targets for diagnosis, prognostication, and treatment of IPMN.
UR - http://www.scopus.com/inward/record.url?scp=84876419071&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2012.11.016
DO - 10.1016/j.surg.2012.11.016
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84876419071
SN - 0039-6060
VL - 153
SP - 663
EP - 672
JO - Surgery (United States)
JF - Surgery (United States)
IS - 5
ER -